

**Maryland Board of Pharmacy
Public Board Meeting**

**Meeting Minutes
August 21, 2019**

Name	Title	Present	Absent
Ashby, D.	Commissioner		
Bouyoukas, S.	Commissioner		X
Evans, K.	Commissioner		
Hardesty, J.	Commissioner/Treasurer		
Laws Jr, A.	Commissioner		
Leikach, N.	Commissioner		
Morgan, K.	Commissioner/President		X
Oliver, B.	Commissioner		
Rusinko, K.	Commissioner		
Toney, R.	Commissioner/Secretary		
Yankellow, E.	Commissioner		X
Bethman, L.	Board Counsel		
Felter, B.	Staff Attorney		
Speights-Napata, D.	Executive Director		
Fields, E.	Deputy Director of Operations		
James, D.	Licensing Manager		
Leak, T.	Compliance Director		
Clark, B.	Legislative Liaison		X
Chew, C.	Management Associate		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>c. Licensing staff</p> <p>d. Independent Pharmacist vacancy</p> <p>2. Staff Training/Certification Update</p> <p>3. Upcoming Holiday Closure</p>	<p>1c. Licensing has two new employees joining the Board on September 4 and September 11.</p> <p>1d. Applications are being accepted; the deadline is September 9.</p> <p>2a. Pharmacy inspector Michelle Taylor and pharmacist investigator supervisor Donna Goldberg will complete their CLEAR certification inspector and investigator training next month. Trina Leak and Jered Pasay attended the USP training and workshops. Other staff have participated in training and staff development.</p> <p>3a. In observance of Labor Day, the Board office will be closed September 2.</p>	
B. Operations Report	E. Fields, Deputy Director/ Operations	<p>1. Procurement and Budget Updates a: July 2019 Financial Statements</p> <p>2. Management Information Systems (MIS) Unit Updates a: None</p>	<p>1a. A report on board revenue for July was provided.</p> <p>2a. Registration for the CE Breakfast posted to the Board's website.</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
---------	-------------------	------------	----------------------------------	---------

C. Licensing	D. Ashby, Commissioner	1. Unit Updates																																																				
		2. Monthly Statistics																																																				
		<table border="1"> <thead> <tr> <th data-bbox="567 397 772 487">License Type</th> <th data-bbox="772 397 873 487">New</th> <th data-bbox="873 397 997 487">Renewed</th> <th data-bbox="997 397 1131 487">Reinstated</th> <th data-bbox="1131 397 1234 487">Total</th> </tr> </thead> <tbody> <tr> <td data-bbox="567 487 772 568">Distributor</td> <td data-bbox="772 487 873 568">15</td> <td data-bbox="873 487 997 568">70</td> <td data-bbox="997 487 1131 568">0</td> <td data-bbox="1131 487 1234 568">1,334</td> </tr> <tr> <td data-bbox="567 568 772 649">Pharmacy</td> <td data-bbox="772 568 873 649">22</td> <td data-bbox="873 568 997 649">0</td> <td data-bbox="997 568 1131 649">0</td> <td data-bbox="1131 568 1234 649">2,056</td> </tr> <tr> <td data-bbox="567 649 772 730">Pharmacist</td> <td data-bbox="772 649 873 730">99</td> <td data-bbox="873 649 997 730">497</td> <td data-bbox="997 649 1131 730">0</td> <td data-bbox="1131 649 1234 730">12,194</td> </tr> <tr> <td data-bbox="567 730 772 812">Vaccination</td> <td data-bbox="772 730 873 812">35</td> <td data-bbox="873 730 997 812">90</td> <td data-bbox="997 730 1131 812">0</td> <td data-bbox="1131 730 1234 812">4,717</td> </tr> <tr> <td data-bbox="567 812 772 925">Pharmacy Intern - Graduates</td> <td data-bbox="772 812 873 925">4</td> <td data-bbox="873 812 997 925">0</td> <td data-bbox="997 812 1131 925">0</td> <td data-bbox="1131 812 1234 925">47</td> </tr> <tr> <td data-bbox="567 925 772 1039">Pharmacy Intern - Students</td> <td data-bbox="772 925 873 1039">29</td> <td data-bbox="873 925 997 1039">3</td> <td data-bbox="997 925 1131 1039">0</td> <td data-bbox="1131 925 1234 1039">822</td> </tr> <tr> <td data-bbox="567 1039 772 1120">Pharmacy Technician</td> <td data-bbox="772 1039 873 1120">127</td> <td data-bbox="873 1039 997 1120">338</td> <td data-bbox="997 1039 1131 1120">3</td> <td data-bbox="1131 1039 1234 1120">9,885</td> </tr> <tr> <td data-bbox="567 1120 772 1226">Pharmacy Technician Student</td> <td data-bbox="772 1120 873 1226">0</td> <td data-bbox="873 1120 997 1226">0</td> <td data-bbox="997 1120 1131 1226">0</td> <td data-bbox="1131 1120 1234 1226">34</td> </tr> <tr> <td data-bbox="567 1226 772 1307">TOTAL</td> <td data-bbox="772 1226 873 1307">346</td> <td data-bbox="873 1226 997 1307">1,016</td> <td data-bbox="997 1226 1131 1307">5</td> <td data-bbox="1131 1226 1234 1307">31,193</td> </tr> </tbody> </table>			License Type	New	Renewed	Reinstated	Total	Distributor	15	70	0	1,334	Pharmacy	22	0	0	2,056	Pharmacist	99	497	0	12,194	Vaccination	35	90	0	4,717	Pharmacy Intern - Graduates	4	0	0	47	Pharmacy Intern - Students	29	3	0	822	Pharmacy Technician	127	338	3	9,885	Pharmacy Technician Student	0	0	0	34	TOTAL	346	1,016	5	31,193
		License Type			New	Renewed	Reinstated	Total																																														
		Distributor			15	70	0	1,334																																														
		Pharmacy			22	0	0	2,056																																														
		Pharmacist			99	497	0	12,194																																														
		Vaccination			35	90	0	4,717																																														
		Pharmacy Intern - Graduates			4	0	0	47																																														
		Pharmacy Intern - Students			29	3	0	822																																														
		Pharmacy Technician			127	338	3	9,885																																														
		Pharmacy Technician Student			0	0	0	34																																														
TOTAL	346	1,016	5	31,193																																																		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
D. Compliance	T. Leak, Compliance Director	<p>1. Unit Updates</p> <p>2. Monthly Statistics</p> <p>Complaints & Investigations:</p> <p>New Complaints -32</p> <ul style="list-style-type: none"> • Professional Misconduct -2 • Medication Error - 1 • Refusal to Fill -3 • Applicant -2 • Child Support - 2 • Dispensing Errors- 5 • Customer Service - 2 • Refusal to Fill - 2 • Disciplinary Action in Another State - 2 • Dispensing Error - 1 • Employee Pilferage -4 • Facility Issues - 1 • Fraudulent Prescriptions - 2 • Inspection Issues - 9 • Resolved (Including Carryover) - 48 • Actions within Goal -38/48 • Final disciplinary actions taken -11 • Summary Actions Taken -11 • Average days to complete -0 <p>Inspections:</p> <p>Total - 127</p> <p>Annual Inspections - 115</p> <p>Opening Inspections - 6</p> <p>Closing inspections - 2</p> <p>Relocation/Change of Ownership Inspections - 2</p> <p>Board Special Investigation Inspections - 2</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
E. Legislation & Regulations	B. Clark, Legislative Liaison	<p><u>Regulations:</u> None</p> <p><u>Legislation:</u> None</p>		
<p>III. Committee Reports</p> <p>A. Practice Committee</p>	K. Evans, Commissioner	<p>Nancy Fingerhut: As you may be aware, there is significant regulatory movement in the compounding industry. United States Pharmacopoeia (USP) published revised chapters on nonsterile compounding <795> and sterile compounding <797>. In addition, FDA continues to make efforts to finalize the Memorandum of Understand (MOU) for state Boards of Pharmacy to sign, regarding interstate distribution of compounded medications. In light of these changes, our pharmacy would like clarification on both topics:</p> <p>1. Will the Board enforce the new 2019 USP <795> and <797> chapters, effective December 1, 2019, or maintain the adopted standard of the current 2015 version?</p> <p>2. If Board review and adoption of USP 2019 chapters is required, is there a timeline for when this will occur? Does the Board anticipate adopting in full or in part, if at all?</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>practitioner or business doing business in Maryland with Maryland patients, you will be subject to Maryland laws and regulations.</p> <p>Ronald Keech: When will the Maryland Board of Pharmacy decide if it will adopt and enforce USP 800?</p> <p>The owner of the store does not want to do construction if it is not going to be enforced.</p> <p>Can you let me know if it will be enforced or not? The time is running out for us to build before the December 1 deadline.</p> <p>Also, we want to give our patients at least a month notice to find a pharmacy that is USP 800 compliant if it will be enforced.</p> <p>Proposed response: The Board is not currently enforcing USP-800 specifically; however, please be advised that provisions that overlap with USP-797 will be enforced.</p> <p>Farzana Musawwir: I work at a heart failure clinic under UMMC, Currently this clinic has a non-regulatory status. Advance heart failure patients are seen in this clinic and have infusion at times, based on need. Often time's patient needs to go home with a few doses of oral K supplement, or diuretic supply based on weekend or situation. Clinic has a small inventory of medications of such urgent need. I would like to have some clarification on what we can do as pharmacists in this clinic. Questions are:</p>	<p>After a brief discussion, a motion was made by D. Ashby to approve draft response; 2nd by N. Leikach</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>1. Are we able to manage the inventory of these medications</p> <p>2. Are Pharmacist or Pharmacy technicians under supervision of RPh eligible to dispense medications from this inventory for patient to take home? If yes, which are the criteria? If not, who can dispense and under which criteria?</p> <p>Proposed response: 1) Generally, yes.</p> <p>2) No. Pharmacists may not dispense outside of a licensed pharmacy; however, a pharmacist may apply to dispense from a clinic under a drug therapy management contract, pursuant to COMAR 10.34.31.</p> <p>Wendy Crump: I am writing to you on behalf of Merck and Sanofi Pasteur. We are currently finalizing arrangements to distribute a new pediatric vaccine, VAXELIS, into your state. VAXELIS is the first hexavalent pediatric vaccine approved in the US. The partners would like to designate Sanofi Pasteur as the entity that will handle distribution into your state and across the US, and are writing to confirm that we will be able to obtain all the necessary licensure. The facts of the arrangement are specified below.</p> <p>1. MCM, an unincorporated unpopulated Pennsylvania partnership, holds the BLA for VAXELIS. 2. Sanofi Pasteur owns 50% of MCM, with Merck holding the other 50%. 3. Sanofi Pasteur is considered an affiliate of MCM and a manufacturer of VAXELIS under 21 U.S. Code § 360eee of the Federal Food, Drug, and Cosmetic Act.</p>	<p>Motion by R. Toney to approve draft response 2nd by D. Ashby.</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>4. Sanofi Pasteur is the contracted manufacturer of VAXELIS and produces & packages VAXELIS on behalf of MCM.</p> <p>5. At all points prior to sale, an affiliate of Sanofi Pasteur (MCM) will hold title to VAXELIS.</p> <p>6. Sanofi Pasteur will have physical control of VAXELIS at all points from final packaging until delivery.</p> <p>7. At time of delivery, Sanofi Pasteur will have the ability to pass title of VAXELIS to the customer.</p> <p>8. Sanofi Pasteur will have the authority to pass title to the customer through a consignment agreement with MCM.</p> <p>9. All invoicing, payment, and delivery will be done by Sanofi Pasteur, on Sanofi Pasteur letterhead.</p> <p>10. Sanofi Pasteur will handle all recalls and returns.</p> <p>11. At all times, Sanofi Pasteur will be jointly and severally liable for all MCM debts as per Pennsylvania Partnership Law.</p> <p>12. At all times, Sanofi Pasteur will be jointly responsible for FDA reporting on VAXELIS.</p> <p>13. Sanofi Pasteur has a valid state manufacturer license in PA. (Sanofi Pasteur, Inc. One Discovery Drive; Swiftwater, PA 18370 Certificate(s): 1000001086 issued: 1/1/1978 expires: 12/31/2019; 8000000069 issued: 9/1/1994 expires: 12/31/2019)</p> <p>14. Sanofi Pasteur has a valid license to distribute drug product into your state as a manufacturer.</p> <p>Given these set of facts, we are seeking an answer to whether Sanofi Pasteur will be able to distribute VAXELIS into your state under its existing license? Sanofi Pasteur will submit such additional applications or information as you request to support the claims above and to ensure our license properly reflects that we are distributing VAXELIS.</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>Proposed response: The business that you have described would require a long-form distributor application. Under Md. Code Ann., Health Occ. § 12-6C-03(2), manufacturers may only distribute their own drugs that they hold title to. In this case, it is a 50% owned subsidiary that holds title. Therefore, the long-form application is required.</p> <p>Maryland Board of Pharmacy Rehabilitation Services Program: Committee has revised notice for Board posting to reflect COMAR regulation 10.34.10.05.</p>	<p>Motion by B. Oliver to approve draft response 2nd by K. Rusinko.</p>	<p>The Board voted to approve this motion.</p> <p>Information updated on the Board's website.</p>
<p>B. Licensing Committee</p>	<p>S. Bouyoukas, Co-Chair</p>	<p>1. Review of Pharmacist Applications:</p> <p>a. #116555- The applicant's MDBOP application expired on 04/11/2019. She is requesting the Board grant her an extension of her NAPLEX score transfer (08/02/2017) and MDBOP application. The score is valid for one year from the date of examination which expired 08/02/2018. She took the MPJE exam and passed on 07/02/2019. She has moved and had two deaths in her family. The applicant does hold an active license in DC. The Licensing Unit did inform the applicant of options. <u>Committee's Recommendation: Approve 3 month extension of NAPLEX score and MDBOP application</u></p> <p>b. #122376- The applicant is requesting ADA testing accommodations for the MPJE and NAPLEX exams. He has been diagnosed</p>	<p>1a) Recommendation by committee to approve 3-month extension; 2nd by N. Leikach.</p> <p>1b) Recommendation by committee to approve; 2nd by K. Evans.</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>with ADHD and he is easily distracted. He would like a separate testing room. <u>Committee's Recommendation: Approve</u></p> <p>c. #115787- The applicant is requesting the Board approve an extension of her NABP ATT number (Authorization to Test) which is due to expire on (08/20/2019) and additional preparation time for the MPJE exam. The applicant indicated that she has been recently diagnosed with Graves' disease. She must frequently report for routine lab-work, f/u doctor appointments, ultrasounds, etc... She does not feel adequately prepared to sit for any exam prior to 08/20/2019. <u>Committee's Recommendation: Approve, 6-month extension of the NABP ATT number</u></p> <p>d. #117672- (Withdrawn Exam application packet on 06/18/2019) - The Board has approved two prior NAPLEX score extension request. Her NAPLEX score expired on or about 12/27/2018. Extensions were granted on 01/16/2019 until 02/28/2019 & 04/18/2019 until 06/30/2019. The applicant is requesting via email, a third NAPLEX score transfer extension. She states that she has no options available to enable her to retake the NAPLEX, as a single parent struggling with no job. <u>Committee's Recommendation: Approve, 3-month extension (12/2019)</u></p> <p>e. #07771- The licensee renewed his license online on 07/10/2019. The licensee is requesting a refund of his renewal fee of \$261. He is aware that the Board has a non-</p>	<p>1c) Recommendation by committee to approve 6-month extension; 2nd by R. Toney.</p> <p>1d) Recommendation by committee to approve a 3-month extension; 2nd by N. Leikach.</p> <p>1e) Recommendation by committee to deny; 2nd by B. Oliver.</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>refundable policy. <u><i>Committee's Recommendation: Deny</i></u></p> <p>f. #12437- The expired pharmacist is requesting the Board grant her approval to pay the renewal fee of \$261, instead of being charged the reinstatement fee of \$524. She states that her license expired on 06/30/2019, which was a Sunday. Her renewal application was postmarked 7/1/2019. She states that her family experienced an unexpected loss on 06/15/2019, when her mother-in-law passed away in Nigeria. She traveled to Nigeria for the funeral on 07/04/2019 and purchased her ticket on 06/26/2019. <u><i>Committee's Recommendation: Approve</i></u></p> <p>g. #118733- The applicant's MPJE exam extension request was reviewed by the Licensing Committee on July 3, 2019. <u><i>Committee's Recommendation: Approve a 6-month extension.</i></u></p> <p>2. Review of Pharmacy Intern Applications: NONE</p> <p>3. Review of Pharmacy Technician Applications: NONE</p> <p>4. Review of Distributor Applications: a. #D06504- Company is requesting waiver of the reinstatement fee (1,500). Company's permit was issued 01/31/2019. Company was made aware permit was going to expire 05/31/2019 and required the submission of a renewal application. Renewal application was received by the Board 07/22/2019. <u><i>Committee's Recommendation: Deny</i></u></p>	<p>1f) Recommendation by committee to approve; 2nd by R. Toney. A brief discussion followed concerning a grace period for submission of renewal applications.</p> <p>1g) Recommendation by committee to approve; 2nd by B. Oliver.</p> <p>4a) Recommendation by committee to deny; 2nd by R. Toney.</p>	<p>The Board voted to approve this motion.</p> <p>Referred to Licensing Committee.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>b. #D05163- Company is requesting waiver of the reinstatement fee (1,500). The renewal application was received 05/09/2019 without the fee. An email was sent 05/09/2019, requesting the renewal fee. The renewal fee was received 07/29/2019. The due date of the renewal was 05/31/2019. <u>Committee's Recommendation: Deny</u></p> <p>5. Review of Pharmacy Applications: NONE</p> <p>6. Review of Pharmacy Technicians Training Programs:</p> <p>a. NHA ExCPT-New training Module (Online) Does the Board want to review updates to the programs. Full update is 2, 130 pages.</p> <p>b. Pillbox- <u>Committee's Recommendation: Deny the program does not meet MDBOP requirements</u></p> <p>c. Greensboro Pharmacy Inc. <u>Committee's Recommendation: Approve</u></p> <p>7. Review of Contraception Training Programs:</p> <p>a. COMAR section that outlines approval criteria 10.34.40.01-6</p>	<p>4b) Recommendation by committee to deny; 2nd by N. Leikach</p> <p>Tabled until September board meeting.</p> <p>Recommendation by D. Ashby to deny 2nd by R. Toney.</p> <p>Recommendation by committee to approve; 2nd by B. Oliver.</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>b. APHA Program Birth Control Pharmacist program <u>Committee's Recommendation: Approve</u> Kris Rusinko and Daniel Ashby Recused</p> <p>8. New Business:</p> <p>a. BS-I have a question about reciprocating licenses. When a pharmacist that is licensed in another state reciprocates their license to Maryland, are they able to shadow another licensed pharmacist until their license is granted by The Board?</p> <p>I have a few candidates for hire at Trivergent Health Alliance that are in the process of reciprocating their license to Maryland. They have applied for reciprocation already and have completed all requirement with exception of passing the MJPE. (Our question is, until they are licensed, are they allowed to shadow a licensed pharmacist in order to learn our workflow and processes.) They would not be dispensing medication, providing education to patients, or any other functions of a pharmacist until they are licensed in the State of Maryland. Our HR department is looking for something in writing from The Board stating that they are able to be onsite to learn workflow so long as they are not performing any duties of a pharmacist. Could you please help us with this issue?</p>	<p>Recommendation by committee to approve; 2nd by B. Oliver.</p>	<p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p><i>Committee Recommended Response:</i> Provided that a pharmacist applicant is not practicing pharmacy or engaged in any other type of patient care requiring licensure, an applicant can begin employment and orientation with a pharmacy. The Board lacks any jurisdiction to prohibit otherwise.</p> <p><i>Committee's Recommendation: Approve</i></p> <p>b. ES- Requestor was requesting to open a Pharmacy Waiver. To provide immunization in businesses to churches, schools, and other venues. <i>Committee's Recommendation: Board Response:</i></p> <p>Dear ES:</p> <p>The Board of Pharmacy has received your application for a waiver pharmacy permit for a business that would administer influenza and other vaccinations to its patients.</p> <p>After reviewing your inquiry and proposed business model, the Board has determined that a pharmacy permit is not required to establish the business that you have proposed. In fact, the proposed business does not meet Maryland's legal definition of a pharmacy, as it would not compound, dispense or distribute prescription or nonprescription drugs (HO 12-101(t)).</p> <p>Though the business that you have proposed does not meet the definition of a pharmacy and thus does not require a</p>	<p>Recommendation by committee to approve; 2nd by R. Toney.</p> <p>Recommendation by committee to approve draft response; 2nd by B. Oliver.</p>	<p>The Board voted to approve this motion.</p> <p>The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
		<p>permit from the Board, the Board does not prohibit a pharmacist from establishing or working for such a business (COMAR 10.34.32.03). For further information on establishing such a business, you may wish to employ a private attorney to help you determine an appropriate business entity and navigate any legal requirements for such a business.</p>		
C. Public Relations Committee	R.Toney, Co-Chair	<p>Public Relations Committee Update:</p> <ul style="list-style-type: none"> • Commissioner R. Toney provided the update of the meeting held on July 24. • Newsletter distribution is being tested through constant contact. • CE Breakfast speakers have been confirmed for October 20. • The September Board/staff luncheon has been finalized. September Board meeting will include board/staff appreciation and lunch. 		
D. Disciplinary	J. Hardesty Chair	<p>Disciplinary Committee Update:</p> <ul style="list-style-type: none"> • Committee met August 7. • A confidential discussion will be held in the Board's Closed Public Session. 		
E. Emergency Preparedness Task Force	N. Leikach, Chair	<p>Emergency Preparedness Task Force Update: NONE</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned to)	Results
IV. Other Business & FYI	J. Hardesty, Commissioner			
V. Adjournment	J. Hardesty, Commissioner	<p>A. The Public Meeting was adjourned at 10:13 am.</p> <p>B. J. Hardesty convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications.</p> <p>C. The Closed Public Session was adjourned. Immediately thereafter, K. Morgan, convened an Administrative Session for purposes of discussing confidential disciplinary cases.</p> <p>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session</p>	Motion to close the Public Board Meeting by D. Ashby; 2 nd by K. Evans.	The Board voted to approve this motion.

**PRESIDING OFFICER'S WRITTEN STATEMENT FOR CLOSING A MEETING ("CLOSING STATEMENT")
UNDER THE OPEN MEETINGS ACT (General Provisions Article § 3-305)**

This form has two sides. Complete items 1 - 4:

1. Recorded vote to close the meeting: Date: 8/21/19; Time: 10:13; Location: 4701 Petterson Ave.
Motion to close meeting made by: D. Ashby Seconded by R. Evans;
Members in favor: UNANIMOUS; Opposed: —;
Abstaining: —; Absent: F. Vankellow, K. Morgan, S. Benyukals

2. Statutory authority to close session (check all provisions that apply):

This meeting will be closed under General Provisions Art. § 3-305(b) only:

(1) ___ "To discuss the appointment, employment, assignment, promotion, discipline, demotion, compensation, removal, resignation, or performance evaluation of appointees, employees, or officials over whom this public body has jurisdiction; any other personnel matter that affects one or more specific individuals"; (2) ___ "To protect the privacy or reputation of individuals concerning a matter not related to public business"; (3) ___ "To consider the acquisition of real property for a public purpose and matters directly related thereto"; (4) ___ "To consider a matter that concerns the proposal for a business or industrial organization to locate, expand, or remain in the State"; (5) ___ "To consider the investment of public funds"; (6) ___ "To consider the marketing of public securities"; (7) "To consult with counsel to obtain legal advice"; (8) ___ "To consult with staff, consultants, or other individuals about pending or potential litigation"; (9) ___ "To conduct collective bargaining negotiations or consider matters that relate to the negotiations"; (10) ___ "To discuss public security, if the public body determines that public discussion would constitute a risk to the public or to public security, including: (i) the deployment of fire and police services and staff; and (ii) the development and implementation of emergency plans"; (11) ___ "To prepare, administer, or grade a scholastic, licensing, or qualifying examination"; (12) ___ "To conduct or discuss an investigative proceeding on actual or possible criminal conduct"; (13) "To comply with a specific constitutional, statutory, or judicially imposed requirement that prevents public disclosures about a particular proceeding or matter"; (14) ___ "Before a contract is awarded or bids are opened, to discuss a matter directly related to a negotiating strategy or the contents of a bid or proposal, if public discussion or disclosure would adversely impact the ability of the public body to participate in the competitive bidding or proposal process."

Continued →

For a meeting recessed to perform an administrative function (§ 3-104): Time: 11:15 AM
 Place: 4201 Eastern Ave. Persons present: all present in open unless listed
 Subject matter: discussed: Complaint investigations

Persons attending closed session: All members present at prior session unless listed
 Authority under § 3-305 for the closed session: (§ 3-305(b)(13))
 Topics actually discussed: License applications containing confidential information
 Actions taken: passed applications accordingly
 Each recorded vote: UNANIMOUS

Members who voted to meet in closed session: UNANIMOUS
 Purpose(s): to review in matters, review committee deliberations re: license applications containing confidential information
 session: 10:13 AM Place: 4201 Eastern Ave. Baltimore

WORKSHEET FOR OPTIONAL USE IN CLOSED SESSION: INFORMATION THAT MUST BE DISCLOSED IN THE MINUTES OF THE NEXT OPEN MEETING Time of closed

4. This statement is made by John J. Hardy,
 Presiding Officer.

Reason for closed-session discussion of topic	Topic	Creation (insert # from above)
		§ 3-305(b) (1)
		§ 3-305(b) (1)
		§ 3-305(b) (1)
	Practice inquiry	§ 3-305(b) (1)
Engage in medical review committee deliberations regarding confidential matters contained in applications	Reviewing applications for licensure	§ 3-305(b) (1)
Definitive legal advice re: standard of practice inquiry	Practice inquiry	§ 3-305(b) (1)

3. For each provision checked above, disclosure of the topic to be discussed and the public body's reason for discussing that topic in closed session.